vTv Therapeutics Expands Global HPP737 Rights with Newsoara

vTv Therapeutics ( (VTVT) ) just unveiled an announcement.

On January 30, 2026, vTv Therapeutics LLC amended its 2018 license agreement with Newsoara Biopharma, restoring and significantly expanding Newsoara’s rights to develop and commercialize the PDE4 inhibitor HPP737 on a worldwide basis, contingent on a $20 million upfront payment. Under the revised terms, vTv stands to receive up to $50 million in development milestone payments, $65 million in sales-related milestones, and mid-single-digit royalties on sales, positioning the company to secure substantial non-dilutive funding and broader global exposure for HPP737, with potential upside for both its revenue profile and partnership-driven growth strategy.

The most recent analyst rating on (VTVT) stock is a Buy with a $47.00 price target. To see the full list of analyst forecasts on vTv Therapeutics stock, see the VTVT Stock Forecast page.

Spark’s Take on VTVT Stock

According to Spark, TipRanks’ AI Analyst, VTVT is a Neutral.

The score is held down primarily by weak financial performance (minimal revenue, large losses, and consistent cash burn) despite low leverage. Technicals provide meaningful support due to a clear uptrend and positive momentum indicators, while valuation is constrained by negative earnings and no dividend support.

To see Spark’s full report on VTVT stock, click here.

More about vTv Therapeutics

vTv Therapeutics LLC, a subsidiary of vTv Therapeutics Inc., operates in the biopharmaceutical industry and focuses on developing small-molecule drug candidates, including the PDE4 inhibitor HPP737, through partnerships and licensing deals with regional and global pharmaceutical companies such as Newsoara Biopharma.

Average Trading Volume: 15,848

Technical Sentiment Signal: Buy

Current Market Cap: $148M

See more data about VTVT stock on TipRanks’ Stock Analysis page.